scholarly journals Cost-effectiveness of paediatric influenza vaccination in the Netherlands

2020 ◽  
Author(s):  
Pieter T. de Boer ◽  
Franklin C.K. Dolk ◽  
Lisa Nagy ◽  
Jan C. Wilschut ◽  
Richard Pitman ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Cost Saving ◽  
Influenza Vaccination ◽  
Vaccination Programme ◽  
Risk Groups ◽  
Inactivated Vaccine ◽  
Vaccination Strategies ◽  
Clinical Risk ◽  
Vaccine Type ◽  
Clinical Risk Groups

AbstractBackgroundThis study evaluates the cost-effectiveness of extending the Dutch influenza vaccination programme for elderly and clinical risk groups to include paediatric influenza vaccination, taking indirect protection into account.MethodsAn age-structured dynamic transmission model was used that was calibrated to influenza-associated GP visits over four seasons (2010/11 to 2013/14). The clinical and economic impact of different paediatric vaccination strategies were compared over 20 years, varying the targeted age range, the vaccine type for children and the vaccine type for elderly and clinical risk groups. Outcome measures include averted symptomatic infections and deaths, societal costs and quality-adjusted life years (QALYs), incremental cost-effectiveness ratios, and net health benefits (NHBs), using a willingness-to-pay threshold of €20,000 per QALY gained.ResultsAt an assumed coverage of 50%, adding vaccination of 2- to 17-year-olds with quadrivalent-live-attenuated influenza vaccine (Q-LAIV) to the current influenza vaccination programme was estimated to avert on average 406,270 symptomatic cases and 83 deaths per season compared to vaccination of elderly and risk groups with trivalent inactivated vaccine (TIV), and was cost-saving (cumulative 20-year savings of 36,396 QALYs and €1,680 million; NHB: 120,411 QALYs). This strategy dominated paediatric vaccination strategies targeting 2- to 6-year-olds or 2- to 12-year-olds, or paediatric vaccination strategies with TIV. The highest NHB was obtained when 2- to 17-year-olds were vaccinated with Q-LAIV and existing target groups switched from TIV to quadrivalent inactivated vaccine (NHB: 132,907 QALYs).ConclusionModelling indicates that paediatric influenza vaccination reduces the disease burden of influenza substantially and is cost-saving.

scholarly journals Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands

2015 ◽  
Vol 46 (5) ◽  
pp. 1407-1416 ◽  
Author(s):  
Marie-Josée J. Mangen ◽  
Mark H. Rozenbaum ◽  
Susanne M. Huijts ◽  
Cornelis H. van Werkhoven ◽  
Douwe F. Postma ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
High Risk ◽  
The Netherlands ◽  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Pneumococcal Disease ◽  
Community Acquired Pneumonia ◽  
Base Case ◽  
Vaccination Strategies ◽  
Vaccine Type

The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) demonstrated the efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) in preventing vaccine-type community-acquired pneumonia and vaccine-type invasive pneumococcal disease in elderly subjects. We examined the cost-effectiveness of PCV13 vaccination in the Netherlands.Using a Markov-type model, incremental cost-effectiveness ratios (ICER) of PCV13 vaccination in different age- and risk-groups for pneumococcal disease were evaluated using a societal perspective. Estimates of quality-adjusted life-years (QALYs), costs, vaccine efficacy and epidemiological data were based on the CAPiTA study and other prospective studies. The base-case was PCV13 vaccination of adults aged 65–74 years compared to no vaccination, assuming no net indirect effects in base-case due to paediatric 10-valent pneumococcal conjugate vaccine use. Analyses for age- and risk-group specific vaccination strategies and for different levels of hypothetical herd effects from a paediatric PCV programme were also conducted.The ICER for base-case was €8650 per QALY (95% CI 5750–17 100). Vaccination of high-risk individuals aged 65–74 years was cost-saving and extension to medium-risk individuals aged 65–74 years yielded an ICER of €2900. Further extension to include medium- and high-risk individuals aged ≥18 years yielded an ICER of €3100.PCV13 vaccination is highly cost-effective in the Netherlands. The transferability of our results to other countries depends upon vaccination strategies already implemented in those countries.

scholarly journals Age Dependence of Prostate Cancer Clinical Risk Groups

2019 ◽  
Vol 105 (1) ◽  
pp. E275
Author(s):  
C.H. Feng ◽  
M.P. Huynh-Le ◽  
T.Å. Myklebust ◽  
T.B. Johannesen ◽  
A.M. Dale ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Risk Groups ◽  
Age Dependence ◽  
Clinical Risk ◽  
Clinical Risk Groups

scholarly journals Gasto farmacéutico en diabetes mellitus en una región de España según el Clinical Risk Group, 2012

2016 ◽  
Vol 15 (30) ◽  
Author(s):  
Luis Alvis Estrada ◽  
David Vivas-Consuelo ◽  
Vicent Caballer-Tarazona ◽  
Ruth Usó-Talamantes ◽  
Carla Sancho-Mestre ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Risk Group ◽  
Risk Groups ◽  
Clinical Risk ◽  
Clinical Risk Groups

<p>Se pretende estimar la multimorbilidad asociada con diabetes mellitus tipo 2 y su relación con el gasto farmacéutico, para lo cual se realizó un estudio de corte transversal durante el año 2012. Se identificó a 350 015 individuos diabéticos, a través de códigos clínicos, usando la Clasificación Internacional de Enfermedades y el software 3M Clinical Risk Groups. Todos los pacientes fueron clasificados en cuatro grupos de morbilidad. El primer grupo corresponde al estadio inicial, el segundo grupo incluye el núcleo de multimorbilidad de pacientes en fases intermedia y avanzada, el tercer grupo incluye pacientes con diabetes y enfermedades malignas, y el último grupo es de pacientes en estado catastrófico, principalmente enfermos renales crónicos. La prevalencia bruta de diabetes fue de 6,7 %. El gasto promedio total fue de € 1257,1. La diabetes se caracteriza por una fuerte presencia de otras condiciones crónicas y tiene un gran impacto en el gasto farmacéutico.</p>

scholarly journals Immunosurveillance of childhood ALL: polymorphic interferon-γ alleles are associated with age at diagnosis and clinical risk groups

Leukemia ◽  
2004 ◽  
Vol 19 (1) ◽  
pp. 44-48 ◽  
Author(s):  
T Cloppenborg ◽  
M Stanulla ◽  
M Zimmermann ◽  
M Schrappe ◽  
K Welte ◽  
...  
Keyword(s):  
Risk Groups ◽  
Interferon Γ ◽  
Age At Diagnosis ◽  
Childhood All ◽  
Clinical Risk ◽  
Clinical Risk Groups

scholarly journals Seasonal influenza immunisation in Europe. Overview of recommendations and vaccination coverage for three seasons: pre-pandemic (2008/09), pandemic (2009/10) and post-pandemic (2010/11)

2014 ◽  
Vol 19 (16) ◽  
Author(s):  
J Mereckiene ◽  
S Cotter ◽  
A Nicoll ◽  
P Lopalco ◽  
T Noori ◽  
...  
Keyword(s):  
Older People ◽  
Influenza Vaccination ◽  
Pregnant Women ◽  
Vaccination Coverage ◽  
Healthcare Workers ◽  
Seasonal Influenza ◽  
Risk Groups ◽  
European Economic Area ◽  
Clinical Risk ◽  
The Impact

Since 2008, annual surveys of influenza vaccination policies, practices and coverage have been undertaken in 29 European Union (EU)/ European Economic Area (EEA) countries. After 2009, this monitored the impact of European Council recommendation to increase vaccination coverage to 75% among risk groups. This paper summarises the results of three seasonal influenza seasons: 2008/09, 2009/10 and 2010/11. In 2008/09, 27/29 countries completed the survey; in 2009/10 and 2010/11, 28/29 completed it. All or almost all countries recommended vaccination of older people (defined as those aged ≥50, ≥55, ≥59, ≥60 or ≥65 years), and people aged ≥6 months with clinical risk and healthcare workers. A total of 23 countries provided vaccination coverage data for older people, but only 7 and 10 had data for the clinical risk groups and healthcare workers, respectively. The number of countries recommending vaccination for some or all pregnant women increased from 10 in 2008/09 to 22 in 2010/11. Only three countries could report coverage among pregnant women. Seasonal influenza vaccination coverage during and after the pandemic season in older people and clinical groups remained unchanged in countries with higher coverage. However, small decreases were seen in most countries during this period. The results of the surveys indicate that most EU/EEA countries recommend influenza vaccination for the main target groups; however, only a few countries have achieved the target of 75% coverage among risk groups. Coverage among healthcare workers remained low.

scholarly journals Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups

2022 ◽  
Author(s):  
Heather J Whitaker ◽  
Ruby SM Tsang ◽  
Rachel Byford ◽  
Nick J Andrews ◽  
Julian Sherlock ◽  
...  
Keyword(s):  
Immune Response ◽  
Risk Groups ◽  
Vaccine Effectiveness ◽  
Clinical Risk ◽  
Clinical Risk Groups

scholarly journals Predictability of pharmaceutical spending in primary health services using Clinical Risk Groups

Health Policy ◽  
2014 ◽  
Vol 116 (2-3) ◽  
pp. 188-195 ◽  
Author(s):  
David Vivas-Consuelo ◽  
Ruth Usó-Talamantes ◽  
José Luis Trillo-Mata ◽  
Maria Caballer-Tarazona ◽  
Isabel Barrachina-Martínez ◽  
...  
Keyword(s):  
Health Services ◽  
Risk Groups ◽  
Clinical Risk ◽  
Primary Health ◽  
Clinical Risk Groups ◽  
Pharmaceutical Spending ◽  
Primary Health Services

scholarly journals Relación entre la calidad de vida de los pacientes, mediante el cuestionario EuroQol-5D, y la clasificación de morbilidad Clinical Risk Groups

2015 ◽  
Vol 4 (2) ◽  
pp. 47-52
Author(s):  
Daniel Ríos García ◽  
Meritxell Calderó Solé ◽  
Manuel Pena Arnaiz ◽  
Virginia Sánchez Fernández ◽  
Jordi Real Gatius ◽  
...  
Keyword(s):  
Risk Groups ◽  
Clinical Risk ◽  
Calidad De Vida ◽  
Clinical Risk Groups ◽  
Euroqol 5D
Sign in / Sign up

Export Citation Format

Share Document